NanoViricides, Inc. (NNVC) Balance Sheet
NNVC balance sheet, FY2026
June 30, 2026 · U.S. dollars$9.87T assets = $1.19T liabilities + $8.68T equity
Both columns are drawn to the same scale: what NNVC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
NNVC financial health
Current ratio2.66
Comfortable · current assets cover current liabilities 2.66×
Equity / assets87.9%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles3.1%
Mostly tangible · of total assets
Descriptive bands, not a rating. Fiscal FY2026.
NNVC balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $27.0MFY2017 | $9.87TFY2026 | +315.1%/yr | |
| Total liabilities | $6.7MFY2017 | $1.19TFY2026 | +283.2%/yr | |
| Shareholders’ equity | $20.3MFY2017 | $8.68TFY2026 | +322.3%/yr | |
| Cash & short-term investments | $15.1MFY2017 | $2.79TFY2026 | +284.8%/yr | |
| Total debt | $4.0MFY2017 | $94,788FY2022 | −52.6%/yr | |
| Net cash (debt) | $11.1MFY2017 | $14.0MFY2022 | +$2.8M | |
| Working capital | $10.6MFY2017 | $1.97TFY2026 | +$2.0T | |
| Book value per share | $3.87FY2020 | $430,101.55FY2026 | +593.3%/yr | |
| Current ratio | 3.28FY2017 | 2.66FY2026 | −0.62 | |
| Debt / equity | 0.19FY2017 | 0.00FY2022 | −0.19 | |
| Shares outstanding | 5.6MFY2020 | 20.2MFY2026 | +23.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NNVC assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
NNVC liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
NNVC debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
NNVC balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $2.79T | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M |
| Cash & equivalents | $2.79T | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M |
| Short-term investments | — | — | — | — | — | — | — | — | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $58,929 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $368.51B | $112,146 | $172,742 | $295,486 | $350,021 | $307,102 | $277,063 | $270,214 | $240,257 | $131,237 |
| Total current assets | $3.16T | $1.7M | $5.0M | $8.4M | $14.4M | $20.8M | $14.0M | $2.8M | $7.3M | $15.3M |
| Property, plant & equipment (net) | $6.40T | $6.8M | $7.5M | $8.1M | $8.7M | $9.1M | $9.5M | $10.2M | $10.8M | $11.3M |
| Goodwill & intangible assets | $308.77B | $317,039 | $325,308 | $333,578 | $341,848 | $350,118 | $358,388 | $366,658 | $374,929 | $383,198 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.03B | $2,445 | $14,562 | $14,361 | $42,440 | $3,515 | $25,863 | $29,187 | $8,162 | $58,929 |
| Total assets | $9.87T | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M | $23.9M | $13.4M | $18.5M | $27.0M |
| Liabilities | ||||||||||
| Accounts payable | $1.2M | $459,094 | $376,270 | $157,056 | $57,960 | $200,016 | $380,727 | $309,893 | $223,339 | $135,786 |
| Short-term debt | — | — | — | — | $94,788 | $95,306 | $1.1M | $1.6M | — | $4.0M |
| Deferred revenue | — | — | — | — | — | — | — | — | — | $541,366 |
| Total current liabilities | $1.19T | $1.3M | $1.4M | $534,250 | $412,837 | $351,146 | $2.2M | $2.8M | $881,948 | $4.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $1.5M | $0 | $295,322 | $1.5M | $309,893 | $298,092 | $2.0M |
| Total liabilities | $1.19T | $1.3M | $1.4M | $2.0M | $412,837 | $351,146 | $2.2M | $2.8M | $881,948 | $6.7M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $230.0M | $166 | $131 | $116 | $116 | $11,515 | $9,083 | $76,898 | $69,172 | $63,305 |
| Retained earnings (deficit) | −$157.06T | −$148.8M | −$139.4M | −$131.1M | −$122.5M | −$114.4M | −$105.6M | −$92.1M | −$83.7M | −$75.1M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | — | — | −$9 | −$5 | — | — | −$4.6M | −$3.9M | $0 | −$2.5M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $8.68T | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M | $21.8M | $10.6M | $17.7M | $20.3M |
| Key figures | ||||||||||
| Total debt | — | — | — | — | $94,788 | $95,306 | $1.1M | $1.6M | — | $4.0M |
| Net cash (debt) | — | — | — | — | $14.0M | $20.4M | $12.6M | $909,601 | — | $11.1M |
| Working capital | $1.97T | $364,191 | $3.6M | $7.9M | $14.0M | $20.5M | $11.8M | −$22,732 | $6.4M | $10.6M |
| Tangible book value | $8.37T | $7.2M | $11.1M | $14.5M | $22.7M | $29.6M | $21.4M | $10.2M | $17.3M | $19.9M |
| Book value per share | $430,101.55 | $0.50 | $0.97 | $1.28 | $2.00 | $2.74 | $3.87 | — | — | — |
| Shares outstanding | 20.2M | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | 5.6M | — | — | — |
| Current ratio | 2.66 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 |
| Quick ratio | 2.35 | 1.19 | 3.53 | 15.25 | 34.07 | 58.43 | 6.36 | 0.90 | 8.03 | 3.25 |
| Debt / equity | — | — | — | — | 0.00 | 0.00 | 0.05 | 0.16 | — | 0.19 |
| Equity / assets | 87.9% | 85.2% | 89.4% | 88.0% | 98.2% | 98.8% | 91.0% | 78.8% | 95.2% | 75.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $2.79T | $3.2M | $5.2M | $1.1M | $1.6M | $2.5M | $4.0M | $3.9M | $4.8M | $3.3M | $5.2M | $7.0M |
| Cash & equivalents | $2.79T | $3.2M | $5.2M | $1.1M | $1.6M | $2.5M | $4.0M | $3.9M | $4.8M | $3.3M | $5.2M | $7.0M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $368.51B | $164,656 | $145,985 | $126,855 | $112,146 | $184,716 | $113,807 | $175,133 | $172,742 | $258,548 | $72,442 | $173,282 |
| Total current assets | $3.16T | $3.4M | $5.3M | $1.3M | $1.7M | $2.7M | $4.1M | $4.0M | $5.0M | $3.5M | $5.3M | $7.1M |
| Property, plant & equipment (net) | $6.40T | $6.5M | $6.7M | $6.8M | $6.8M | $7.0M | $7.2M | $7.4M | $7.5M | $7.6M | $7.7M | $7.9M |
| Goodwill & intangible assets | $308.77B | $310,836 | $312,904 | $314,971 | $317,039 | $319,106 | $321,174 | $323,241 | $325,308 | $327,376 | $329,443 | $331,511 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.03B | $1,383 | $1,732 | $2,087 | $2,445 | $2,798 | $5,745 | $10,153 | $14,562 | $18,908 | $8,859 | $14,324 |
| Total assets | $9.87T | $10.2M | $12.3M | $8.4M | $8.8M | $10.0M | $11.6M | $11.7M | $12.8M | $11.5M | $13.4M | $15.4M |
| Liabilities | ||||||||||||
| Accounts payable | $1.2M | $1.0M | $1.1M | $254,943 | $459,094 | $1.2M | $1.1M | $1.3M | $376,270 | $341,394 | $266,663 | $229,203 |
| Total current liabilities | $1.19T | $1.1M | $1.2M | $1.2M | $1.3M | $1.2M | $1.2M | $1.6M | $1.4M | $813,337 | $951,074 | $948,311 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.5M |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $1.19T | $1.1M | $1.2M | $1.2M | $1.3M | $1.2M | $1.2M | $1.6M | $1.4M | $813,337 | $951,074 | $2.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $230.0M | $216 | $216 | $176 | $166 | $160 | $156 | $140 | $131 | $118 | $117 | $117 |
| Retained earnings (deficit) | −$157.06T | −$154.8M | −$152.8M | −$150.6M | −$148.8M | −$146.7M | −$144.5M | −$142.5M | −$139.4M | −$137.0M | −$135.2M | −$133.0M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | −$9 | −$9 | −$5 |
| Total shareholders' equity | $8.68T | $9.2M | $11.1M | $7.2M | $7.5M | $8.8M | $10.4M | $10.1M | $11.5M | $10.7M | $12.5M | $13.0M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | — | — | — | — | $1.5M |
| Net cash (debt) | — | — | — | — | — | — | — | — | — | — | — | $5.5M |
| Working capital | $1.97T | $2.3M | $4.1M | $70,180 | $364,191 | $1.5M | $2.9M | $2.4M | $3.6M | $2.7M | $4.4M | $6.2M |
| Tangible book value | $8.37T | $8.8M | $10.8M | $6.9M | $7.2M | $8.5M | $10.1M | $9.8M | $11.1M | $10.3M | $12.1M | $12.6M |
| Book value per share | $430,101.55 | $0.42 | $0.56 | $0.42 | $0.46 | $0.55 | $0.71 | $0.74 | $0.97 | $0.90 | $1.06 | $1.11 |
| Shares outstanding | 20.2M | 21.6M | 19.9M | 17.1M | 16.5M | 16.0M | 14.6M | 13.7M | 11.9M | 11.8M | 11.7M | 11.7M |
| Current ratio | 2.66 | 3.17 | 4.43 | 1.06 | 1.28 | 2.27 | 3.44 | 2.48 | 3.66 | 4.32 | 5.59 | 7.53 |
| Quick ratio | 2.35 | 3.02 | 4.31 | 0.95 | 1.19 | 2.12 | 3.34 | 2.37 | 3.53 | 4.00 | 5.52 | 7.35 |
| Debt / equity | — | — | — | — | — | — | — | — | — | — | — | 0.12 |
| Equity / assets | 87.9% | 89.6% | 90.3% | 85.9% | 85.2% | 88.0% | 89.8% | 86.1% | 89.4% | 92.9% | 92.9% | 84.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 28, 2026); data from EODHD.
NNVC financial position
At the end of fiscal 2026 (June 30, 2026), NanoViricides had total assets of $9.87 trillion (up 111,893,813.1% from a year earlier), total liabilities of $1.19 trillion and shareholders' equity of $8.68 trillion. Its current ratio was 2.66.
Related: NNVC income statement, NNVC cash flow statement, NNVC key metrics. See the NNVC stock overview for the latest quote and news.
NNVC balance sheet FAQ
What are NanoViricides's total assets?
NanoViricides reported total assets of $9.87 trillion at the end of fiscal 2026 (June 30, 2026), compared with $8.8 million a year earlier.
How much cash does NanoViricides have?
NanoViricides held $2.79 trillion in cash and short-term investments at the end of fiscal 2026.
What is NanoViricides's book value?
NanoViricides's shareholders' equity (book value) was $8.68 trillion at the end of fiscal 2026, or $430,101.55 per share.
What is NanoViricides's current ratio?
NanoViricides had current assets of $3.16 trillion and current liabilities of $1.19 trillion, a current ratio of 2.66 (it can cover its short-term obligations).
How much goodwill does NanoViricides have?
NanoViricides carried $308.8 billion of goodwill and intangible assets, 3.1% of total assets, at the end of fiscal 2026.